Riverside Health System's primary responsibility is service to and care of those who trust us to help shape their healthcare choices.
Riverside engages in clinical research to provide health options that may not otherwise be available through standard medical channels. Clinical trials for medications and procedures offer additional resources for health challenges, and contribute to the advancement of medicine. Several clinical trials are currently underway at Riverside, and we are actively recruiting patient participation for the following:
Clostridium difficile (C-diff)
This clinical study will evaluate an investigational vaccine for the prevention of Clostridium difficile infection (C. diff). C. diff is bacterium that causes intestinal disease, and can be potentially life-threatening for older adults. It is the most common cause of infectious diarrhea in hospitals and long-term care facilities, and in rare cases, C. diff may lead to death. Study participants need to be over age 50, have been hospitalized for more than twice in the past year and were prescribed antibiotics or have an upcoming in-patient surgery scheduled. For additional details, contact us at (757) 220-4751 or email the Research Coordinator, Keri Allen, at email@example.com.
Secondary Progressive Multiple Sclerosis (SPMS)
There are currently no FDA-approved treatments for secondary progressive MS and people affected urgently need help. With SPMS there are daily living challenges that often worsen with each flare up, including trouble walking, dealing with pain, fatigue and increased memory issues. A potential treatment option is on the horizon with Riverside's Hampton Roads Neurology as one of only 30 sites in the U.S. and Canada participating in a clinical trial to study an investigational therapy. This therapy uses a patient's own immune cells to help stabilize or stop the progression of the disease. Study participants must be 18-60 years of age, be willing to discontinue current MS therapy, be able to walk with nothing more than a cane and have progression of their MS within the past two years. For additional details, contact us at the (757) 534-5374 or email the Research Coordinator, Cheryl White, at firstname.lastname@example.org.